A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
ConclusionsOur results are consistent with non-clinical studies of ketamine and TAK-063 and clinical studies of ketamine and risperidone. It is unknown whether these data are predictive of potential antipsychotic efficacy, and further analyses are required.
Source: Psychopharmacology - Category: Psychiatry Source Type: research
More News: Brain | Laboratory Medicine | MRI Scan | Neurology | PET Scan | Psychiatry | Risperdal Consta | Schizophrenia | Study